VEGF Analog Receptor Binding Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic treatments for conditions associated with angiogenesis, such as cancer and eye diseases, often result in undesirable side effects due to their mechanisms of action, highlighting the need for novel therapeutics that can effectively inhibit angiogenesis with reduced toxicity.
Innovation Solution
Development of VEGF analogs with increased receptor binding affinity to KDR and decreased bioactivity, achieved through specific amino acid substitutions and modifications, which act as VEGF receptor antagonists to inhibit angiogenesis while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-angiogenic treatments are used to inhibit angiogenesis, then angiogenesis is inhibited, but undesirable side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of VEGF to create analogs with altered binding characteristics. Specifically, mutations are introduced to increase affinity for KDR receptor while decreasing affinity for Flt-1 receptor, thereby changing the selectivity parameter of the drug-receptor interaction. This selective parameter change allows the analogs to inhibit angiogenesis through KDR while avoiding side effects associated with Flt-1 inhibition.
Solution Approach 2:
The patent applies local quality by creating VEGF analogs with non-uniform binding properties across different receptor types. The amino acid substitutions are strategically designed to locally enhance binding to KDR (the predominant angiogenic receptor) while locally reducing binding to Flt-1 (associated with morphogenesis and side effects). This localized differentiation in binding quality enables selective anti-angiogenic activity with reduced toxicity.
2Manufacturing precision
If VEGF analogs with increased receptor binding affinity are developed, then receptor binding affinity to KDR is increased, but bioactivity may increase causing more side effects
Solution Approach 1:
The patent simultaneously changes multiple binding parameters through amino acid substitutions. The analogs are designed with increased binding affinity parameter for KDR (desired) while maintaining decreased binding affinity parameter for Flt-1 (protective). This multi-parameter optimization ensures that high affinity for the therapeutic target does not translate to high affinity for off-target receptors, thereby preventing increased side effects despite enhanced binding.
Solution Approach 2:
The VEGF analogs act as intermediaries with selective receptor preferences. By modifying the VEGF structure, the analogs mediate a selective interaction pattern where they preferentially engage KDR (mediating therapeutic anti-angiogenic effect) while avoiding significant engagement with Flt-1 (mediating morphogenic side effects). This intermediary design with biased selectivity resolves the contradiction between high binding affinity and controlled bioactivity.
3Manufacturing precision
If amino acid substitutions are made to increase KDR binding affinity, then receptor binding affinity is enhanced, but the molecular structure becomes more complex
Solution Approach 1:
The patent achieves enhanced binding affinity through targeted parameter changes in the amino acid sequence rather than through complex structural redesign. Specific amino acid positions are mutated to optimize electrostatic interactions and hydrogen bonding with KDR, achieving high affinity through localized chemical parameter adjustments rather than global structural complexity. This approach maintains relative molecular simplicity while achieving the desired binding enhancement.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.